The past year has seen the rapid global spread of SARS-CoV-2—the virus responsible for the ongoing COVID-19 pandemic. While non-pharmaceutical interventions have been the mainstay of epidemic control to date, vaccination is likely to constitute the definitive, long-term defence strategy against SARS-CoV-2 morbidity, mortality, and transmission, offering the best hope of a return to normal life.
News & Blog
GET TO KNOW US!
AllAllergyAsthmaBest PracticesCase StudiesClinical ResearchCNS/NeurologyConsortiaCriterium NewsData ManagementDermatologyEDCFDAGastroenterologyGlobal Clinical ResearchHematologyIndustry NewsInfectious DiseaseIVR-IWR IxRSMedical DevicesMen's HealthMetabolic SyndromeOncologyOphthalmologyOrphan DiseasesOutsourcingPain ManagementPharmaceutical DevelopmentPress ReleasesPublic InterestTranslational ResearchTrial TechnologyUrologyWomen's Health
Criterium, Inc. Marks 30th Anniversary of Delivering Exceptional Personal Attention and Services for All Clinical Trial Elements
Criterium, Inc. a full-service contract research organization (CRO) dedicated to providing efficiency and expertise in Clinical Trial Services to pharmaceuticals, biotech, and medical device companies throughout the world, celebrates its 30th anniversary.
Criterium's Academic Breast Cancer Consortium (ABRCC) is comprised of 15 renowned academic and community sites in North America, conducting translational research in Breast Cancer studies for major pharmaceutical companies who are working on the most current clinical trials for advanced treatments of breast cancer. While 2020 was a year dominated by COVID-19 news and tragedy, breast cancer research and breakthroughs can't wait for COVID to "go away" – and research in this area continues on full-speed. Our ABRCC researchers reflect on 2020 and look ahead to 2021 with renewed hope.
For November's Lung Cancer Awareness Month, Heather Smith and Melissa Turner share the stories of their cancer journeys. The women took very different routes to the CU Cancer Center and the world-renowned lung cancer care of Ross Camidge, MD. On this episode of the CU Anschutz 360 podcast, learn why they love everything about Dr. Camidge’s practice, especially the fact that he makes them laugh.
Findings from a CHOP/Penn Medicine study could lead to treatment for patients with lung disease, including acute respiratory distress syndrome due to COVID-19.
Moleculin Announces Positive Trial Data with 100% Safe Delivery of p-STAT3 Inhibitor and Efficacy in Majority of Patients Preliminary results from phase 1 clinical trial of WP1220 for treatment of
- Tracking COVID-19 Vaccine Development Efforts Across the Globe
- Criterium, Inc. Marks 30th Anniversary of Delivering Exceptional Personal Attention and Services for All Clinical Trial Elements
- What’s New in Breast Cancer Research and Treatment?
- Podcast: ‘You Have to Personalize the Miracles’
- Researchers Identify “Druggable” Signaling Pathway that Stimulates Lung Tissue Repair